Crossbow Therapeutics is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets.
Crossbow Therapeutics
TAP Partner
Cambridge, Massachusetts
United States
Project Title
A phase 1 study of CBX-250, a TCR-mimetic antibody, in patients with AML, MDS or CMML
Program
Therapy Acceleration Program